Evidence map›Paper›PMID 35389241›Full record

ArticleMicrobiology spectrum2022

Toward Optimization of a Rabbit Model of Staphylococcus aureus (USA300) Skin and Soft Tissue Infection.

Natalia Malachowa, Will McGuinness, Scott D Kobayashi, Adeline R Porter, Carl Shaia, Jamie Lovaglio, Brian Smith, Viktoria Rungelrath, Greg Saturday, Dana P Scott and 4 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Anti-infective compounds forSustainable microbiology · 2026
    Review
  2. The future of phage therapy in the USA.Trends in molecular medicine · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Natalia MalachowaLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Will McGuinnessLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Scott D KobayashiLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Adeline R PorterLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Carl ShaiaRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Jamie LovaglioRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Brian SmithRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Viktoria RungelrathLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Greg SaturdayRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Dana P ScottRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Fabiana FalugiDepartment of Microbiology, University of Chicago, Chicago, Illinois, USA.
Dominique MissiakasDepartment of Microbiology, University of Chicago, Chicago, Illinois, USA.ORCID 0000-0001-6482-9633
Olaf SchneewindDepartment of Microbiology, University of Chicago, Chicago, Illinois, USA.
Frank R DeLeoLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.ORCID 0000-0003-3150-2516

Funding

Mechanisms of Staphylococcus aureus virulenceZIAAI001079 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DELEO, FRANK · 2009 to 2025
$11.8M
Vaccine Assembly from Surface Proteins of Staphylococcus AureusR01AI052474 · NIAID · UNIVERSITY OF CHICAGO · PI Dominique Missiakas · 2002 to 2026
$8.8M
NIAID NIH HHS R01 AI052474
6 · The paper itself

Abstract

Staphylococcus aureus remains a leading cause of skin and soft tissue infections (SSTIs) globally. In the United States, many of these infections are caused by isolates classified as USA300. Our understanding of the success of USA300 as a human pathogen is due in part to data obtained from animal infection models, including rabbit SSTI models. These animal models have been used to study S. aureus virulence and pathogenesis and to gain an enhanced understanding of the host response to infection. Although significant knowledge has been gained, the need to use a relatively high inoculum of USA300 (1 × 10

Indexed as

Methicillin-Resistant Staphylococcus aureusSoft Tissue InfectionsStaphylococcal InfectionsStaphylococcal Skin InfectionsVaccinesAnimalsRabbitsReinfectionStaphylococcus aureusUnited StatesVaccinesabscessanimal modelMRSArabbitrecurrent infectionStaphylococcus aureusUSA300

Identifiers

PMID35389241
PMCPMC9045089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.